TKI biotech lays out plans to raise about $125M in IPO; Hookipa sets terms for upsized $100M IPO

→ San Diego-based Turning Point Therapeutics has laid out terms for its IPO, planning to sell 7.4 million shares at a range of $16 to $18 a share. Renaissance Capital reports that insiders expect to take about 40% of a total of around $125 million, which would give the oncology biotech a valuation of more than $500 million. They’ll sell shares under the $TPTX symbol. The biotech is developing a pipeline of tyrosine kinase inhibitors.

Hookipa Biotech is shooting for $100 million in an upsized IPO, having announced a price range of $14 to $16 for 6.7 million shares for its offering under the symbol $HOOK. The raise will fund the New York-based company’s immunotherapies — a clinical program in cytomegalovirus infection and preclinical ones for immuno-oncology — while it works on HBV and HIV programs for partner Gilead. At the midpoint of the proposed range, Renaissance Capital reports, it would command a valuation of $412 million.

Sanofi has decided to take an autoimmune therapy developed by Schrödinger into the clinic, triggering a milestone payment to the computational drug design shop as written out in their collaboration pact.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->